Print Page  |  Close Window

Overview

BioTelemetry provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.

The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.

Recent NewsMore >>
DateTitle 
05/24/17BioTelemetry, Inc. Increases Tender Offer Price and Extends Offer Period for LifeWatch AG Shares
MALVERN, Pa. and ZUG, Switzerland, May 24, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the Company has increased the price of its previously announced public tender offer for all outstanding shares of LifeWatch AG (SIX:LIFE).  As revised, shareholders of LifeWatch will receive either CHF10.00 in cash and 0.1617 sha... 
Printer Friendly Version
05/23/17BioTelemetry, Inc. Announces Extension of the Tender Offer Period for LifeWatch AG Shares
MALVERN, Pa., May 23, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that, in accordance with the provisions of the Offer Prospectus and at the Company’s request, the Swiss Takeover Board has extended the initial main offer period of the tender offer to acquire all of the shares of LifeWatch AG (SIX:LIFE), which was schedu... 
Printer Friendly Version
05/10/17BioTelemetry, Inc. Announces the Start of the Tender Offer Period for LifeWatch AG Shares
MALVERN, Pa. and ZUG, Switzerland, May 10, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the start of the main offer period of the tender offer to acquire all of the shares of LifeWatch AG (SIX:LIFE).  The main offer period is scheduled to expire at 4:00 p.m. CEST, on May 23, 2017.  It will be open for a period of ten tra... 
Printer Friendly Version
05/08/17BioTelemetry, Inc. Announces Receipt of Antitrust Clearance for its Acquisition of LifeWatch AG
MALVERN, Pa. and ZUG, Switzerland , May 08, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) announced today that, effective on May 5, 2017, it received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to its previously announced tender offer to acquire all of the capital stock of LifeWatch AG (SIX:LIFE).  This clearance comes without any condition on or undertaking by BioTelemetry, LifeWatch or any ... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.